Vertex Pharmaceuticals, a clinical-stage biopharmaceutical company, recently announced that two Phase 3 studies evaluating its tezacaftor/ivacaftor combination therapy have shown statistically significant and clinically meaningful improvements in lung function in patients with certain mutations associated with cystic fibrosis (CF). The first study, called EVOLVE (NCT02347657), was conducted to…
Two preclinical studies support the ability of Synspira’s lead candidate SNSP113 to prevent bacteria from forming treatment-resistant layers (biofilms), and in reducing mucus viscosity and easing clearance, new data show. These findings, presented at the 31st Annual North American Cystic Fibrosis Conference (NACFC) taking place in Indianapolis through…
Corbus Pharmaceuticals recently announced that the U.S. Patent and Trademark Office has issued a patent for the use of anabasum, the company’s lead therapy candidate for the treatment of inflammatory and fibrotic diseases. Anabasum is a synthetic oral endocannabinoid-mimetic drug that binds to a receptor called cannabinoid receptor…
Pulmatrix recently announced that it is presenting positive preclinical data on its antifungal therapy Pulmazole at the North American Cystic Fibrosis Conference (NACFC) (Nov. 2-4, 2017). Pulmazole (PUR1900) is based on itraconazole, an antifungal drug, combined with an innovative technology developed by Pulmatrix called iSPERSE, which is a dry powder…
Vertex Pharmaceuticals announced a $750,000 addition to its cystic fibrosis (CF) research innovation program that supports the work of young scientists aiming to establish themselves as independent CF researchers. The initiative expands the company’s CF Research Innovation Awards (RIA) program furthering post-doctoral research that aims to advance the understanding…
Orkambi (lumacaftor/ivacaftor) reduced levels of the main biomarker of the lung disease cystic fibrosis and improved the nutritional status of children with the condition, according to a Phase 3 clinical trial. The results were part of a recent update that Vertex Pharmaceuticals provided on Orkambi and three of its…
Children’s National Health System no longer treats just kids. Its Rare Disease Institute, launched in April 2017, has partnered with the National Organization for Rare Disorders (NORD) to become the first of many U.S. “centers of excellence” to look after patients with rare diseases, regardless of age. The effort…
About 4,400 researchers, doctors, patients and others from 46 countries are converging on Indianapolis for the 31st Annual North American Cystic Fibrosis Conference — the world’s largest gathering dedicated to cystic fibrosis research and care. The Nov. 2-4 event at the Indiana Convention Center will feature more than 350 sessions and…
Polyphor and the European Innovative Medicines Initiative (IMI) will fund up to 10 million euros (around $11.6 million U.S.) to support and advance the development of an inhaled formulation of Polyphor’s investigational antibiotic murepavadin (POL7080). Polyphor is investing 5 million euros into the development project; the IMI will provide up…
A new tool allows researchers and doctors to visualize a 3D model of a cystic fibrosis (CF) lung that incorporates information about microbes, which may help improve targeted drug delivery, a new study shows. The study, “Three-Dimensional Microbiome and Metabolome Cartography of a Diseased Human Lung,”…
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Get regular updates to your inbox.